Stephen W. Mason

2100 Cunard Street
Laval, H7S2G5, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Journal: ACS medicinal chemistry letters

Published: May 11, 2016

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Journal: ACS medicinal chemistry letters

Published: March 15, 2014

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Journal: ACS medicinal chemistry letters

Published: January 03, 2014

Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes.

Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes.

Journal: Antimicrobial agents and chemotherapy

Published: July 03, 2013

Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Journal: Antimicrobial agents and chemotherapy

Published: April 03, 2013

Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography.

Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography.

Journal: ACS chemical biology

Published: March 19, 2013

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

Journal: Bioorganic & medicinal chemistry letters

Published: February 08, 2013

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Journal: Bioorganic & medicinal chemistry letters

Published: February 08, 2013

A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.

A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.

Journal: Acta crystallographica. Section D, Biological crystallography

Published: January 28, 2013

Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2:1 inhibitor/NC stoichiometry.

Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2:1 inhibitor/NC stoichiometry.

Journal: Journal of molecular biology

Published: January 18, 2013

Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine series.

Monitoring binding of HIV-1 capsid assembly inhibitors using (19)F ligand-and (15)N protein-based NMR and X-ray crystallography: early hit validation of a benzodiazepine series.

Journal: ChemMedChem

Published: December 17, 2012

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Journal: Bioorganic & medicinal chemistry letters

Published: August 27, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026